- Thapsigargin-stimulated lad2 human mast cell line is a potent cellular adjuvant for the maturation of monocyte-derived dendritic cells for adoptive cellular immunotherapy2021 | Second Faculty of Medicine
- Adoptive cellular immunotherapy with targeted drugs2000 | First Faculty of Medicine
- Active cellular immunotherapy of ovarian cancer using dendritic cells2012 | Second Faculty of Medicine
- LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy2022 | Second Faculty of Medicine
- Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer2018 | Second Faculty of Medicine, First Faculty of Medicine
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial2021 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- Report of University Hospital Hradec Králové to the clinical trial protocol No: SP001Publication without faculty affiliation
- Current Approaches in Cancer Immunotherapy2015 | First Faculty of Medicine
- Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies2022 | Central Library of Charles University, Faculty of Science
- Trial Watch Dendritic cell-based interventions for cancer therapy2013 | Second Faculty of Medicine
- High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy2017 | Second Faculty of Medicine
- SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors2021 | Second Faculty of Medicine
- Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy2017 | Second Faculty of Medicine, First Faculty of Medicine
- Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype2020 | Second Faculty of Medicine, First Faculty of Medicine
- Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial2021 | First Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial2022 | Faculty of Medicine in Hradec Králové